Immatics N.V.

NASDAQ:IMTX

Biotechnology

Healthcare
$6.10 +1.58%

+$0.15 today

Market cap
$912.78M
Beta
1.30
P/E (TTM)
-5.3
EPS (TTM)
-$1.59
52W Low $5.05High $12.41

Volume 1.57M

Average 0.46M

IMTX Income Before Tax

Profit after all operating and non-operating items but before income tax.

Immatics N.V.NASDAQ: IMTX

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -€57.76M, compared with -€40.85M a year earlier. Trailing-twelve-month income before tax was -€215.35M.

Context

  • Income before tax amounted to 411.1% of revenue in FY2025, up 397.4 pp from a year earlier.
  • Income before tax increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -€57.76M or moves back toward the trailing-twelve-month quarterly average of -€53.84M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-€57.76M-62.4% QoQ
Last fiscal yearDec 2025
-€198.44M-1029.6% YoY
LTMMar 2026
-€215.35M-1111.0% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-41.4%——
1 year-1029.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

EUR · from the income statement

Latest · FY2025
(198.44M) EUR
Year-over-year change
-1029.6%

Income Before Tax vs competitors

How IMTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -1111.0% is the lowest of 11, against a peer median of +15.9%.
  • Income before tax amounts to 577.4% of revenue for IMTX, versus a peer median of 98.7%.
IMTX Competitors
Income Before Tax for IMTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$32.2M USD+114.5%—2.4%
IMCRImmunocore Holdings plcLTM Mar 2026-$7.82M USD+65.7%—2.0%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026-$9.44M USD+39.8%—40.8%
DTILPrecision BioSciences, Inc.LTM Mar 2026-$44.49M USD-102.3%—98.7%
CLLSCellectis S.A.LTM Mar 2026-$69.45M USD-15.2%—102.0%
JANXJanux Therapeutics, Inc.LTM Mar 2026-$114.48M USD-47.3%—529.7%
TCRXTScan Therapeutics, Inc.LTM Mar 2026-$124.31M USD+5.5%—1360.6%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026-$173.76M USD+31.0%——
IMTXImmatics N.V.LTM Mar 2026-€215.35M EUR-1111.0%—577.4%
LYELLyell Immunopharma, Inc.LTM Mar 2026-$246.41M USD+26.3%—794858.1%
BNTXBioNTech SELTM Jun 2026-€1.64B EUR-321.6%—61.9%
Peer median (excluding IMTX) —+15.9%—98.7%

Competitors are the stored peer set for IMTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue34.76M172.83M54M155.84M48.27M
Cost of Revenue87.57M106.78M118.66M00
Gross Profit(52.81M)66.05M(64.67M)155.84M48.27M
Gross Margin-151.9%38.2%-119.8%100.0%100.0%
Research & Development87.57M106.78M118.66M148.08M183.83M
Selling, General & Admin33.81M36.12M38.2M46.45M51.18M
Operating Expenses121.05M142.88M155.72M194.45M230.28M
Depreciation & Amortization5.47M6.84M7.23M12.23M12.4M
EBITDA(87.3M)50.04M(88.93M)34.46M(185.09M)
EBITDA Margin-251.1%29.0%-164.7%22.1%-383.5%
Operating Income(86.29M)29.95M(101.73M)(38.62M)(182.02M)
Operating Margin-248.2%17.3%-188.4%-24.8%-377.1%
Interest Income133K2.48M13.85M25M17.18M
Interest Expense566K1.04M831K886K946K
Other Income / Expenses(7.04M)12.08M4.73M59.96M(16.42M)
Income Before Tax(93.34M)42.04M(96.99M)21.35M(198.44M)
Pre-Tax Margin-268.5%24.3%-179.6%13.7%-411.1%
Income Tax Expense04.55M06.13M(1.99M)
Net Income(95.06M)37.51M(96.99M)15.22M(196.45M)
Net Margin-273.5%21.7%-179.6%9.8%-407.0%
EPS (Basic)(1.51)0.55(1.20)0.14(1.54)
EPS (Diluted)(1.51)0.54(1.20)0.14(1.54)
Weighted Avg Shares62.91M67.22M80.55M108.7M122.35M
Weighted Avg Shares (Diluted)62.91M68.82M80.55M106.8M122.35M

Immatics N.V.

NASDAQ:IMTX

Intrinsic Alpha fair value

Locked

Current Price

$6.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.